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Renoprotection with and without blood pressure reduction.
Background. AT1-receptor blockade dose dependently low-
ers blood pressure (BP) and albuminuria. Reduction of BP and
albuminuria are independent treatment targets for renoprotec-
tion, but whether this requires similar dose titration is unknown.
Methods. We tested this in two studies designed to find the
optimal antialbuminuric dose of losartan in type 1 diabetic
(DM, N = 50) and nondiabetic renal patients (ND, N = 12).
After baseline, treatment followed with losartan 50, 100, and
150 mg/day, each dose for eight (DM) or six weeks (ND). At the
end of each period, albuminuria (24-hour samples) and mean
arterial pressure (MAP) were measured. Patients were divided
into “good” and “poor” BP responders (BP+, BP−) according
to BP response above or below group median.
Results. Baseline MAP in the BP− groups was 102 (97, 104)
mm Hg in DM (median, 95% CI) and 91 (80, 108) mm Hg in
ND. The top of the dose response for BP (obtained at losartan
100 mg) in the BP− groups was −2 (−4, 3) mm Hg in DM
and –1 (−6, 2) mm Hg in ND, versus −15 (−18, −12) mm Hg
and −16 (−26, −18) mm Hg in BP+ groups (both P < 0.05).
Albuminuria was reduced dose dependently both in BP− and
BP+: with 100 mg, the reduction in albuminuria in DM BP−
was −32% (−49, 13) versus −45% (−60, −38) in DM BP+ and
−45% (−70,−7) versus –25% (−58, −6) in ND BP− and BP+
(all P > 0.05). Moreover, in patients in whom BP fell below the
recommended treatment target of 130/80 mm Hg (13 in DM and
10 in ND), albuminuria was progressively reduced, with further
increasing the dose of losartan in most patients.
Conclusion. Absence of BP response to losartan does not
preclude a reduction in albuminuria, and optimal reduction of
albuminuria may require titration beyond the predefined BP
target.
Raised blood pressure [1] and proteinuria [2] are mod-
ifiable risk factors in progressive renal function loss in
diabetic, as well as nondiabetic, renal disease. It is well
recognized that lowering blood pressure with antihyper-
tensive treatment slows progressive renal function loss
[3]. Additional lowering of proteinuria by specific antihy-
pertensive treatment regimens like renin-angiotensin sys-
tem (RAS) blockade is associated with a slower decline of
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renal function compared to other treatment groups with
similar blood pressure [4, 5]. Thus, it has been argued
that reduction of blood pressure and proteinuria should
be independent treatment goals [6].
RAS blockade with ACE inhibitors or angiotensin II,
type 1 receptor blockers (ARB) is so far the most effective
pharmacologic tool for long-term renoprotection. These
agents have the advantage of reducing proteinuria more
effectively than other antihypertensives do [7].
As these drugs were originally introduced as antihy-
pertensives, it is still common practice to titrate the dose
of these agents to reach a prespecified blood pressure tar-
get. However, we [8, 9] and others [10, 11] have shown
that proteinuria, too, is sensitive to the dose of these
drugs, and the optimal dose for proteinuria may not al-
ways be similar to that for blood pressure. Importantly,
there is considerable interindividual variability, both in
the antihypertensive response [12] and the antiprotein-
uric response [13] to RAS blockade. Presumably, the an-
tiproteinuric response is, to a certain extent, dependent
from the effect on systemic blood pressure. This does not
automatically imply, however, that the observed interpa-
tient variability in the blood pressure and antiprotein-
uric response are concordant. In other words, whether
a good—or poor—blood pressure response is always ac-
companied by a respectively good—or poor—response
for proteinuria in a given patient is unknown so far. In
the present analyses, therefore, we tested first whether
dose-dependent reduction of proteinuria is concordant
with the blood pressure dose-response to RAS block-
ade with the ARB losartan. Second, we tested whether
achievement of a predefined blood pressure target (i.e.,




Individual patient data were used from two recent stud-
ies that were designed to find the optimal dose of losar-
tan for reduction of proteinuria [8, 9]. The study designs
and inclusion criteria of the original investigations have
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Table 1. Patient characteristics in subgroups according to break-up for blood pressure response
Diabetic patients Nondiabetic patients
Good BP responders Poor BP Responders Good BP responders Poor BP responders
(N = 21) (N = 22) (N = 6) (N = 6)
Age years 43 (41, 52) 43 (40, 50) 45 (39, 51) 53 (43, 59)
Male/female 17/4 11/11 3/3 4/2
Albuminuria g/day 1.3 (1.0, 2.3) 1.2 (0.9, 1.7) 4.5 (3.0, 6.9) 2.4 (1.7, 3.8)a
Systolic BP mm Hg 161 (152, 169) 150 (143, 155)a 142 (126, 163) 127 (113, 152)
Diastolic BP mm Hg 84 (80, 88) 79 (73, 82)a 82 (74, 96) 74 (63, 87)
MAP mm Hg 108 (104, 113) 102 (97, 104)a 102 (91, 118) 91 (80, 108)
GFR 87 (74, 102) 96 (84, 102) 82 (46, 100) 85 (61, 104)
Na excretion mmol/day 171 (151, 193) 138 (129, 172) 115 (83, 146) 120 (80, 159)
aP < 0.05 vs. good BP responders. No comparisons were made between diabetic and nondiabetic patients.
been shown extensively in the original papers. In short,
the first was a study in 50 patients with type 1 diabetes
mellitus and nephropathy (DM), and the second study
was performed in 12 nondiabetic patients (ND) with var-
ious glomerular disorders and proteinuria. Only patients
with diastolic blood pressure between 80 and 110 mm
Hg were included. Two nondiabetic patients that fulfilled
the same protocol were included in the present analy-
ses. The protocols were largely similar, and started with
a washout period of four to six weeks before enrollment
in the study (withdrawal of all antihypertensives). Then,
treatment with losartan was followed according to fixed
dosing steps. All patients were treated with 50, 100, and
150 mg/day losartan, and each dose was used for eight
(DM) or six weeks (ND). Data were collected at the end
of each period. Blood pressure was measured by 24-hour
ambulatory measurements (DM), or with a Dinamap de-
vice after 15 minutes of supine rest (ND). Renal function
was assessed by [51Cr] EDTA plasma clearance (DM)
or by calculating creatinine clearance from 24-hour urine
(ND). Albuminuria was measured from at least two 24-
hour urine collections (Cobas Mira Plus; Roche, Mont-
clair, NJ, USA). In order to allow comparison of baseline
albuminuria, random urine samples were exchanged be-
tween both laboratories for measurement of albuminuria,
and a conversion factor was established, yielding a cor-
relation with R2 = 0.98. Albuminuria in the nondiabetic
patients was then calculated by this conversion factor. In
both studies, the use of antihypertensives, other than the
study drug, was not allowed.
The responses of blood pressure and albuminuria
are expressed as percentage change from baseline (me-
dian and 95%CI). Comparison of the antialbuminuric
response between groups was performed using Mann-
Whitney U test, and comparisons within groups were
performed using Wilcoxon signed rank test. Differences
were considered significant if P < 5%.
Analysis 1: Antialbuminuric dose response in the “poor”
and “good” blood pressure responders
First, we questioned whether interindividual variabil-
ity in the dose response of blood pressure and albumin-
uria were concordant. To test this, groups of “poor” and
“good” BP responders were defined. Patients from both
studies were separated into two groups according to the
blood pressure response by calculating the average re-
sponse to the three doses used in each patient. Patients
were then, according to the group median, attributed to
the group of poor BP responders or good BP respon-
ders. Then, the effect on albuminuria of increasing doses
of losartan was tested in good and poor responders. Be-
cause the protocols were not entirely similar, the data on
the diabetic and nondiabetic patients were not pooled
and are presented separately.
Analysis 2: Step-up dosing beyond the blood pressure
target: effect on albuminuria
The second question was whether the use of predefined
blood pressure criteria in treating renal patients results in
optimal reduction of proteinuria. To answer this, we es-
tablished at each dose that patients were below the prede-
fined target blood pressure, and then evaluated whether
further increases of the losartan dose led to a further de-
crease of albuminuria. The target used is the target for
type 1 diabetic patients with renal involvement as formu-
lated by the American Diabetes Federation (i.e., a systolic
BP ≤130 mm Hg and a diastolic BP ≤80 mm Hg).
RESULTS
Antialbuminuric dose response in the “poor”
and “good” blood pressure responders
From the original study in diabetic patients, 43 patients
with complete blood pressure registrations were eligible
for the present analysis, while all 12 nondiabetic patients
were included. The 7 diabetic patients not included in
the present analysis had baseline GFR 88 mL/min and
albuminuria 1.3 g/day (range: 0.3, 4.0 g/day) and the re-
duction of albuminuria was –38% (range: –91, 16%).
These characteristics were not different from those of
the included diabetic patients, shown in Table 1. The pa-
tients from both populations were middle-aged, and had
mild to moderately impaired renal function. In nondia-
betic patients, baseline albuminuria was higher than in
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Fig. 1. The antialbuminuric response (gray bars) and blood pressure response (white bars) at each dosing step, represented as%∆ from baseline,
in the total population of diabetic and nondiabetic patients. The upper part of the graph shows the subgroup of “good BP responders,” the lower
part of the graph shows the subgroup of “poor BP responders” (i.e., a BP response above or below the median of the total population, respectively).
the diabetic patients. The good BP responders of both
populations tended to have a higher baseline blood pres-
sure compared to the poor blood pressure responders,
but this difference reached statistical significance only in
the diabetic patients.
The responses of proteinuria and blood pressure are
depicted in Figure 1. In the poor BP responders, that
is, a BP response below the median, the blood pres-
sure response was virtually absent across all three dosing
steps. As expected, a clear-cut blood pressure response
was observed in the group designated good BP respon-
ders, confirming that the break-up by the median indeed
effectively identified “poor” and “good” responders.
Interestingly, albuminuria was reduced considerably
and dose dependently in the “poor” BP responders: the
antialbuminuric response by the 100 mg dose was higher
than by the 50 mg dose (both 100 mg vs. 50 mg dose, P <
0.01), and the 150 mg dose had no additional benefit at
group level.
The antialbuminuric response of poor BP responders
is given separately for the diabetic and nondiabetic pa-
tients in Table 2. It shows that albuminuria was reduced
in both subsets of patients without a blood pressure re-
sponse. Possibly due to the size of the subgroups, both
in the diabetic and nondiabetic patients, there was no
clear difference between the antialbuminuric efficacy in
the poor BP responders versus the good BP responders.
Step-up dosing beyond the blood pressure target: effect
on albuminuria
In the diabetic patients, only 13 out of 43 reached the
blood pressure target of 130/80 mm Hg during the pro-
tocol. Ten out of the 12 nondiabetic patients reached
the blood pressure target. The antialbuminuric responses
of the patients that reached the target blood pressure
of 130/80 mm Hg are shown in Figure 2 (diabetic pa-




Diabetic −15% (−28, 13) −32% (−49, 13)a −30 (−47, 17)a
Nondiabetic −21% (−51, 12) −45% (−70, −7)a −32% (−61, −1)a
aP < 0.05 vs. baseline.
tients) and Figure 3 (nondiabetic patients). The target
was reached without antihypertensive medication in two
(DM) and five (ND) patients. In the patients who were
on target without therapy (Figs. 2A and 3A), a consider-
able decrease in albuminuria was observed with increas-
ing the losartan dose. In the patients that reached the
target at the 50 mg dose of losartan (Figs. 2B and 3B),
increasing the dose resulted in further reduction of albu-
minuria in all but one patient. In patients that reached
target blood pressure at the 100 mg dose (Figs. 2C and
3C), additional antialbuminuric benefit was observed in
the majority (i.e., six out of nine patients), by increasing
the dose to 150 mg. In summary, there was a general ten-
dency that increasing losartan beyond the dose at which
target blood pressure was reached resulted in additional
reduction of albuminuria.
In the patients that did not reach the blood pressure
target at the consecutive dosing steps (30/43 diabetics
and 2/12 nondiabetics), this did not preclude a significant
reduction of albuminuria. The median fall in albumin-
uria in the diabetic patients was −22% (−29; −9), −34%
(−43; −20), and −38% (−42; 5) with losartan 50, 100, and
150 mg/day, respectively (all doses: P < 0.05 vs. baseline,
and 50 vs. 100 mg dose: P < 0.05).
DISCUSSION
For long-term renoprotection, antihypertensive treat-
ment with RAS blockade has the major advantage of its
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Fig. 2. The effect on albuminuria (%∆ from baseline) of step-wise increasing the dose of losartan in individual diabetic patients who reached the
target BP of 130/80 mm Hg. The vertical dotted lines indicate the dose at which target BP has been reached. (A) Patients who reached target BP
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Fig. 3. The effect on albuminuria (%∆ from baseline) of step-wise increasing the dose of losartan in individual nondiabetic patients who reached
the target BP of 130/80 mm Hg. The vertical dotted lines indicate the dose at which target BP has been reached. (A) Patients who reached target
BP at baseline. (B) Patients who reached target BP at the 50 mg dose. (C) Patients who reached target BP at the 100 mg dose.
specific antiproteinuric effect. Blood pressure and pro-
teinuria are both considered independent treatment tar-
gets, but it is currently unknown how to titrate RAS
blockade to bend the curve of renal function loss.
One issue of importance in this respect, addressed in
the present study, is whether the blood pressure lower-
ing effect and antiproteinuric effect run in parallel in in-
dividual patients. This study shows that the opposite is
true, that is, a clinically important antiproteinuric dose
response can be observed in patients that are basically
nonresponsive with respect to systemic blood pressure,
even at high doses of the ARB losartan. Moreover, in the
subset of patients who had already reached the desired
blood pressure, a further increment in the dose resulted
in a progressive fall in proteinuria in most subjects.
It must be stressed that secondary analyses like ours
must be considered with caution and need to be con-
firmed in prospective follow-up studies. Nevertheless, the
findings on the effect of the ARB on blood pressure
response and albuminuria were consistent between the
larger diabetic group and the smaller nondiabetic group.
It also must be stressed that the response of albumin-
uria and blood pressure to ARB was measured at three
consecutive doses. Thus, absent or poor blood pressure
response is unlikely to have occurred because of random
fluctuations. Because the data were obtained in two sep-
arate populations with different renal diseases, this indi-
cates that our findings are not limited to a single center
or method of data collection (e.g., measurement of blood
pressure).
Previous studies have shown that, with low doses, the
antiproteinuric effect obtained with RAS blockade is
more pronounced than would be expected merely from
the effect on systemic blood pressure [7, 14, 15]. By show-
ing that patients who are apparently insensitive with re-
spect to blood pressure have antiproteinuric benefit from
dose titration with RAS blockade, the present report ex-
tends the previous findings usually obtained with low
doses of RAS blockers. It thus provides practical rele-
vance to the increasingly advocated view to consider pro-
teinuria, in addition to blood pressure, as an independent
target for long-term renoprotection [6, 16–18]: because of
the lack of concordance between the responses of both
parameters, optimal reduction of proteinuria is unlikely
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to be reached with the current practice of aiming at pre-
defined levels of blood pressure.
It could be argued that, in order to prevent the possi-
bility of carryover, the doses should have been given in
random order. However, previous studies have shown
that the antiproteinuric effect of losartan reaches its
maxmimum after three to four weeks of treatment [ab-
stract; Preti et al, Am J Hypertens 11:112A, 1998]. Also,
a double-blind cross-over study with losartan 50 and 100
mg in randomized order showed that the magnitude of
the reduction of blood pressure and albuminuria did not
depend on the order of treatment [19].
Interindividual variability in the antiproteinuric re-
sponse to RAAS blockade is increasingly recognized as
an issue, important for improvement of long-term reno-
protective therapy [20, 21], recently reviewed in [22].
The present results do not exclude the possibility that an
individual’s blood pressure response contributes to this
variability. Nevertheless, it is apparent that other factors
must be involved that play a more critical role in this
respect.
It is beyond doubt that blood pressure should be con-
trolled tightly to slow progressive loss of renal function,
both in diabetic and nondiabetic nephropathy [3, 23]. In
addition to blood pressure, proteinuria is the strongest in-
dependent predictor of end-stage renal disease [24], and
regimens reducing proteinuria slow the deterioration of
renal function, independent of the blood pressure effect
[23, 25, 26]. Although all these data indicate that protein-
uria should probably be lowered as much as possible, until
now, no clinical trials addressed whether a regimen pursu-
ing maximal reduction of proteinuria as a treatment goal
allows further improvement of renoprotective efficacy.
In clinical practice, blood pressure targets are hard to
reach, especially in patients with diabetes. In line with this,
in the present study with a fixed step-up dose schedule, 30
out of 43 diabetic patients and 2 out of 12 patients did not
reach the target blood pressure of 130/80 mm Hg. These
patients would, thus, require up-titration, and likely add-
on therapy, for the sake of blood pressure. Nevertheless,
also in these patients a significant fall in albuminuria was
observed.
CONCLUSION
This study with the ARB losartan shows that a fall in
blood pressure is not a prerequisite for a dose-dependent
reduction of proteinuria, both in diabetic and nondia-
betic renal disease. This supports the idea that renopro-
tective treatment should be titrated according to both
blood pressure as well as proteinuria. Large randomized
clinical trials will be necessary to study the long-term re-
nal prognosis of lower proteinuria levels obtained with
such a strategy.
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